FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate CancerJaleh Fallah, Paul G. Kluetz, Gang Niu et al.|Clinical Cancer Research|2022Cited by 236
U.S. FDA Drug Approvals for Breast Cancer: A Decade in ReviewShaily Arora, Julia A. Beaver, Preeti Narayan et al.|Clinical Cancer Research|2021Cited by 73
Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case ExamplesAnup Amatya, Shenghui Tang, Mallorie H. Fiero et al.|Clinical Cancer Research|2021Cited by 29
U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in ReviewShaily Arora, Julia A. Beaver, Preeti Narayan et al.|Clinical Cancer Research|2021Cited by 23